Azvudine, also known as azifodine, was invented by Professor Chang Junbiao and jointly developed by Henan Ruier Biotechnology Co., Ltd., Zhengzhou University, Henan Normal University and High-tech Research Center of Henan Academy of Sciences. It is an HIV reverse transcriptase (RT) inhibitor, which belongs to the world's advanced and domestic first-generation drug for treating AIDS.
In February, 2020, azvudine was found to be anti-COVID-19, and in April, 2020, it was approved by the State Administration of Medical Products to conduct phase III clinical trials against COVID-19. In July, 20021,the anti-HIV drug Afuddin was approved for marketing, which is the first innovative dual-target anti-AIDS drug in the world.
On August 9, 2022, the General Office of the National Health and Wellness Commission and the Office of state administration of traditional chinese medicine issued a notice saying that the drug was included in the "Diagnosis and Treatment Plan of novel coronavirus (Ninth Edition)".
Product advantages:
1, the dosage is small.
At present, (20 13) drugs for AIDS generally need 100 ~ 200mg per day, while afuddin only needs 1mg per day.
2. International innovative drugs.
At present (20 13), all drugs used in China are generic drugs licensed from abroad and can be produced in China. Aftab is an international innovative drug, and its international patents have entered the United States, Europe, Japan, India, South Korea and other countries and regions through PCT.
3. Save the cost of medicine.
Because the cost of drug research and development is lower than that of foreign countries, afudin can greatly reduce the annual treatment cost of AIDS patients. Pre-clinical research shows that compared with the existing anti-AIDS drugs, afudin can block the mutated HIV more effectively, which has the obvious advantages of low drug resistance and high curative effect.